Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) (ERBB2)-directed agents are standard treatments for patients with HER2-positive breast and gastric cancer. Herein, we report the results of an open-label, single-center, phase II basket trial to investigate the efficacy and safety of trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyung, J., Lee, J.Y., Kim, J.E., Yoon, S., Yoo, C., Hong, Y.S., Jeong, J.H., Kim, T.W., Jeon, S., Jun, H.R., Jung, C.K., Jang, J.P., Kim, J., Chun, S.M., Ahn, J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334451/
https://www.ncbi.nlm.nih.gov/pubmed/37327700
http://dx.doi.org/10.1016/j.esmoop.2023.101583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334451/
https://www.ncbi.nlm.nih.gov/pubmed/37327700
http://dx.doi.org/10.1016/j.esmoop.2023.101583

Ejemplares similares